A citation-based method for searching scientific literature

Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Byoung Chul Cho, Myung-Ju Ahn. J Thorac Oncol 2018
Times Cited: 54



Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
Times Cited: 132




List of shared articles



Times cited

Methods for actionable gene fusion detection in lung cancer: now and in the future.
Pasquale Pisapia, Francesco Pepe, Roberta Sgariglia, Mariantonia Nacchio, Gianluca Russo, Gianluca Gragnano, Floriana Conticelli, Maria Salatiello, Caterina De Luca, Ilaria Girolami,[...]. Pharmacogenomics 2021
1


Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
3

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
37


Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.
Ibiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, Jessica J Lin, Emily Chin, Lorin A Ferris, Jennifer Ackil, Jochen K Lennerz, Richard B Lanman, Justin F Gainor,[...]. J Thorac Oncol 2019
57

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer.
Ibiayi Dagogo-Jack, Lauren L Ritterhouse. Transl Lung Cancer Res 2020
4

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
12

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
20

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Yun Shu, Hui Li, Hongjuan Shang, Jun Chen, Xiaoxing Su, Wei Le, Yan Lei, Liming Tao, Cailiang Zou, Wendy Wu. Onco Targets Ther 2020
3

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee,[...]. Clin Cancer Res 2020
34

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib.
Yueming He, Wang Sheng, Weiguo Hu, Jing Lin, Junjun Liu, Bing Yu, Xinru Mao, Lu Zhang, Jin Huang, Guangsuo Wang. Oncol Res 2019
18

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
149

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
4

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
3

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Patrick R Halliday, Collin M Blakely, Trever G Bivona. Curr Oncol Rep 2019
53